MDR1基因多态性与乳腺癌化疗疗效及血液毒性关系的研究  

MDR1 polymorphism predict response and hematologic toxicities in breast cancer patients treated with preoperative chemotherapy

作　　者：季明华[1] 查文武[1] 恽文[2] 李建[3] 赵建华[4] 唐金海[3] 

机构地区：[1]江苏省肿瘤医院放疗科,江苏南京210009 [2]徐州医学院外科系,江苏徐州221004 [3]江苏省肿瘤医院乳腺外科,江苏南京210009 [4]江苏省肿瘤医院江苏省临床检验中心,江苏南京210009

出　　处：《中华肿瘤防治杂志》2012年第10期735-737,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金(30840093)

摘　　要：目的:探讨MDR1基因多态性与乳腺癌患者化疗疗效以及血液毒副反应的关系。方法:筛选70例新辅助化疗的女性患者,利用PCR-RFLP技术检测其外周血MDR1C3435T基因型,分析不同基因型患者化疗后的疗效及血液毒副反应。结果:70例新辅助化疗患者当中,3435TT基因型化疗有效率仅为23.1%,与3435CC和3435CT基因型相比差异有统计学意义(χ2=6.122,P=0.047,95%CI:0.043～0.051);血液毒性方面,3435CC型患者中性粒细胞Ⅲ～Ⅳ度减少的发生率为6.7%,较CT型(37.5%)和TT型(53.8%)发生率低(χ2=7.512,P=0.023,95%CI:0.016～0.021)。结论:携带MDR1 3435C等位基因的患者其化疗疗效可能较好;携带3435T等位基因的患者其中性粒细胞减少的风险可能较高。OBJECTIVE： To investigate whether MDR1 polymorphisms are associated with therapeutic outcome and hematologic toxicities of preoperative chemotherapy in breast cancer patients. METHODS： MDR1 variants were determined in the blood samples from 70 patients by using PCR-RFLP technique. An analysis was carried out among the genotypes and therapeutic outcome and hematologic toxicities. RESULTS： The efficient rate of patients carrying MDR1 3435TT was 23.1% ,significantly lower than those carrying CC or CT（Х^2 =6. 122,P：0. 047,95%CI：0. 043-0. 051）. Patients carrying MDR1 3435CC showed a significantly lower toxicity response rate of Ⅲ- Ⅳ degree neutropenia （6.7 % ） than those with 3435 CT （37.5%）,3435TT（53.8%,Х2=7. 512,P=0. 023,95%CI：0. 016-0. 021）. CONCLUSION： Patients carrying MDR1 3435C allele may have better response to chemotherapy,and those with T allele may have an increased risk of developing neutropenia.

关 键 词：乳腺肿瘤 MDR1 多态性 疗效 毒副反应 

分 类 号：R737.9[医药卫生—肿瘤]